Benign prostate hyperplasia (BPH) and prostate cancer are two major health problems of men in this country. The androgen receptor is critical for both growth and survival of benign and cancerous prostate cells. Mitogenic effects of androgens are mediated in part by androgen-induced increases in proliferation-promoting proteins, such as proliferating cell nuclear antigen (PCNA), cyclin-dependent kinases 2 and 4, as well as decreases in cell cycle inhibitors, such as cyclin-dependent kinase inhibitor p16 ink4a. Although the mechanistic details of the anti-apoptotic effects of androgens are far from elucidated, progress has been made recently in our laboratory and others. We and others have demonstrated that androgens act as survival factors by antagonizing the function of the tumor suppressor gene PTEN. An effector downstream of PTEN, the forkhead transcription factor FKHR, plays a critical role in apoptosis by inducing the transcription of proapoptotic genes. We and others have shown that forced expression of FKHR induces apoptosis in prostate cancer cells, suggesting that FKHR is a critical pro-apoptotic player in prostate cancer cells. Our data have demonstrated that androgens abrogate FKHR-induced death of prostate cancer cells. Moreover, we have demonstrated that androgens inhibit the activity of FKHR by regulating lysosome-mediated proteolysis of this protein. Thus, we hypothesize that androgens antagonize death of prostate cells at least in part via their inhibitory effects on the pro-apoptotic function of FKHR. To test this hypothesis, we propose to (1) determine the proteolytic cleavage site in the FKHR protein; (2) identify the androgen-regulated protease(s) that cleaves FKHR; (3) determine whether blockage of the effect of androgens on FKHR favors the death of prostate cancer cells. These findings should enhance our understanding of the action of androgens on growth and survival of both normal and malignant prostate cells. Also, identification of such novel proteins will enable us to better manipulate androgen-regulated events in BPH and prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK065236-03
Application #
6897791
Study Section
Special Emphasis Panel (ZDK1-GRB-6 (M1))
Program Officer
Mullins, Christopher V
Project Start
2003-08-01
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
3
Fiscal Year
2005
Total Cost
$255,500
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
van der Steen, Travis; Tindall, Donald J; Huang, Haojie (2013) Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci 14:14833-59
Wang, Diping; Lu, Ji; Tindall, Donald J (2013) Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms. Cancer Lett 335:136-44
Nacusi, Lucas P; Tindall, Donald J (2011) Targeting 5?-reductase for prostate cancer prevention and treatment. Nat Rev Urol 8:378-84
Heemers, Hannelore V; Schmidt, Lucy J; Sun, Zhifu et al. (2011) Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. Cancer Res 71:1978-88
Heemers, Hannelore V; Schmidt, Lucy J; Kidd, Emily et al. (2010) Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate 70:959-70
Heemers, Hannelore V; Regan, Kevin M; Schmidt, Lucy J et al. (2009) Androgen modulation of coregulator expression in prostate cancer cells. Mol Endocrinol 23:572-83
Raclaw, Kristin A; Heemers, Hannelore V; Kidd, Emily M et al. (2008) Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. Prostate 68:1696-706
Dehm, Scott M; Schmidt, Lucy J; Heemers, Hannelore V et al. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469-77
Dehm, Scott M; Regan, Kevin M; Schmidt, Lucy J et al. (2007) Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res 67:10067-77
Heemers, Hannelore V; Tindall, Donald J (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778-808

Showing the most recent 10 out of 21 publications